Indirect Assay Patents (Class 435/7.95)
-
Patent number: 7452731Abstract: A method for determining the risk of an individual of suffering from inflammation, opportunistic infection or disruption of immunoglobulin metabolism, comprising (a) determining the level of fragmentation or modification of Fc function of immunoglobulins in a sample taken from the individual and (b) determining thereby the risk of inflammation, impaired immune response or opportunistic infection. The invention also provides the use of a trypsin inhibitor in the manufacture of a medicament for use in the treatment or prevention of a disorder associated with elevated trypsin activity which is correlated with IgG fragmentation or modification.Type: GrantFiled: February 15, 2002Date of Patent: November 18, 2008Inventor: Ivan Mikhailovich Petyaev
-
Patent number: 7449340Abstract: The present invention relates to a method for the early diagnosis of cancer in a subject, which is based on determination of the relative fraction of microorganisms derived from the feces of the subject, as compared to the total count of microorganisms in the same of corresponding sample. This relation has been found to be indicative of the presence or absence of cancer in said subject. After isolating at least one of the microorganisms from the fecal sample to form a so-called diagnostic sample, and incubating, for a sufficient time, the diagnostic sample with cancer cells. The microorganism being in an amount corresponding to its relative fraction in the original fecal sample, the cancerolytic activity of the microorganism/s is indicative to the presence or absence of cancer cells in the subject. The cancerolytic activity is expressed by terms of a tumor cell necrosis index (TCNI).Type: GrantFiled: August 9, 2001Date of Patent: November 11, 2008Assignee: Era-Massis, Inc.Inventors: Gil Tenne, Mark L. Levitt, Anahit Karapetian
-
Patent number: 7442514Abstract: Mutants of the DNA sequence coding for the protease (FSAP) which activates blood clotting factor VII and single-chain plasminogen activators, the mutants comprising a G/C base exchange at nucleotide position 1177 and/or a G/A base exchange at nucleotide position 1601, are described. The corresponding protease has a Glu/Gln exchange at amino acid position 393 and/or a Gly/Glu exchange at amino acid position 534. Diagnostic methods which are used for detecting FSAP in body fluids or tissue cells and also for identifying patients with genetic heterozygous or homozygous FSAP expression are also described. In addition, antibodies against FSAP and its mutants are disclosed and diagnostic methods which can be used to detect antibodies against FSAP and its mutants are specified.Type: GrantFiled: September 1, 2004Date of Patent: October 28, 2008Assignee: CSL Behring GmbHInventors: Juergen Roemisch, Hans-Arnold Stoehr, Annette Feussner, Wiegand Lang, Thomas Weimer, Margret Becker, Claudia Nerlich, Gudrun Muth-Naumann, Bernd Knoblauch
-
Patent number: 7442516Abstract: The present invention provides an antibody which specifically recognizes a CNS tau protein but not a peripheral tau protein. More specifically, the present invention provides an antibody obtainable by using a polypeptide comprising an amino acid sequence of a connective portion between the amino acid sequence encoded by Exon 4 of a gene encoding a tau protein and the amino acid sequence encoded by Exon 5 thereof as an epitope specific to the isoform of tau protein predominantly existing in central nervous tissues. The present invention further provides a method of detecting Alzheimer's disease and a reagent kit using the antibody.Type: GrantFiled: February 11, 2005Date of Patent: October 28, 2008Assignees: Mitsubishi Chemical Corporation, Mitsubishi Kagaku Iatron, Inc.Inventors: Hideto Ohno, Koichi Ishiguro, Masaki Imagawa
-
Patent number: 7432105Abstract: A self-calibrated, magnetic binding assay (e.g., sandwich, competitive, etc.) for detecting the presence or quantity of an analyte residing in a test sample is provided. The magnetic binding assay includes detection probes capable of generating a detection signal (e.g., fluorescent non-magnetic particles) and calibration probes capable of generating calibration signal (e.g., fluorescent magnetic particles). The amount of the analyte within the test sample is proportional to the intensity of the detection signal calibrated by the intensity of the calibration signal.Type: GrantFiled: August 27, 2002Date of Patent: October 7, 2008Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Xuedong Song, Rosann Kaylor
-
Patent number: 7429458Abstract: Bioelastomers are disclosed for use in methods of binding compounds including immunoassay methods, in biosensors and methods or regenerating biosensors, and in methods for targeting the delivery of a compound to a particular location within an animal subjects. In general, the bioelastomer is conjugated to a binding compound, which is in turn used to bind a compound of interest. For targeted compound delivery, the bioelastomer is conjugated to the compound to be delivered.Type: GrantFiled: July 23, 2002Date of Patent: September 30, 2008Assignee: Duke UniversityInventor: Ashutosh Chilkoti
-
Patent number: 7429643Abstract: The application discloses novel polypeptides and nucleic acids involved in a variety of biological processes, including viral reproduction. Related methods and compositions are also described.Type: GrantFiled: January 6, 2005Date of Patent: September 30, 2008Assignee: Proteologics, Inc.Inventors: Iris Alroy, Tsvika Greener, Shmuel Tuvia, Danny Ben-Avraham
-
Patent number: 7416855Abstract: Disclosed are human interleukin-1 ? converting enzyme like apoptosis proteases-3 and 4 and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Also provided are methods of using the polypeptides, for example, as an antitumor agent, and antiviral agent, and antibodies and antagonists against such polypeptides for example, for treating Alzheimer's disease, Parkinson's disease, rheumatoid arthritis and head injury. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases are also disclosed.Type: GrantFiled: March 17, 2004Date of Patent: August 26, 2008Assignee: Human Genome Sciences, Inc.Inventors: Wei-Wu He, Craig A. Rosen, Peter L. Hudson, Gregg A. Hastings
-
Patent number: 7410771Abstract: A reagent and method for the specific and highly sensitive detection of C. parvum in which the reagent is an antibody for a soluble C. parvum sporozoite antigen and the method is an immunoassay in which the antibody is used to detect or quantify C. parvum sporozoite antigen in a sample. The sample is treated to cause excystation of C. parvum oocytes, thereby releasing a C. parvum sporozoite antigen, and combined with antibodies specific for the sporozoite antigen under conditions to form an antibody-antigen complex. Detection of the complex indicates the presence of C. parvum in the sample. The assay allows recognition and detection of C. parvum in turbid samples, and due to a lack of crossreactivity with other Cryptosporidium species, is specific for C. parvum contamination or infection. The assay is highly sensitive, allowing for the detection of less than 100 oocysts per milliliter of sample.Type: GrantFiled: April 14, 2006Date of Patent: August 12, 2008Assignee: The United States of America as represented by the Department of Health and Human Services, Center for Disease Control and PreventionInventors: Victor C. W. Tsang, Jeffrey L. Call, Yeuk-mui Lee, Kathy Hancock
-
Patent number: 7393647Abstract: This invention pertains to methods for detecting B. anthracis and antibodies to B. anthracis, the causative agent of anthrax, in a subject.Type: GrantFiled: May 27, 2003Date of Patent: July 1, 2008Assignee: Biosite IncorporatedInventors: Gunars Edwin Valkirs, Kenneth Buechler
-
Patent number: 7393653Abstract: The present invention provides a method of identifying an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. The method is practiced by contacting a Bit1 polypeptide, or active fragment thereof, and an AES polypeptide, or active fragment thereof, with an agent under conditions that allow the Bit1 polypeptide or active fragment thereof to associate with the AES polypeptide or active fragment thereof; and detecting an altered association of the Bit1 polypeptide or active fragment thereof and the AES polypeptide or active fragment thereof, where an altered association indicates that the agent is an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. Such an effective agent can modulate apoptosis and can be a useful therapeutic agent.Type: GrantFiled: September 5, 2003Date of Patent: July 1, 2008Assignee: The Burnham InstituteInventors: Yiwen Jan, Michelle Matter, Jih-tung Pai, Erkki Ruoslahti
-
Patent number: 7390627Abstract: Immunoassays for malondialdehyde-modified low density lipoprotein (MDA-modified LDL) and oxidized low density lipoprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.Type: GrantFiled: June 12, 2007Date of Patent: June 24, 2008Assignee: Leuven Research & Development VZWInventors: Paul Noel Holvoet, Désiré José Collen
-
Patent number: 7390626Abstract: ELISA, Western Blot, and a peptide-based ELISA were applied to clinical specimens from patients with clinical symptoms of tick borne diseases, including Lyme disease. Peptides from different components of Borrelia during different cycles, including peptides from outer surface protein, leukocyte function associated antigens, immunodominant antigens, variable major proteins, and peptides from decorin-binding proteins of Borrelial subspecies (B. sensu stricto. B. afzelii, B. garinii) were used. Antibodies against specific peptides from Babesia and Ehrlichia were also measured.Type: GrantFiled: February 25, 2005Date of Patent: June 24, 2008Assignee: Immunosciences Lab., Inc.Inventor: Aristo Vojdani
-
Patent number: 7374888Abstract: This invention pertains to methods for detecting B. anthracis and antibodies to B. anthracis, the causative agent of anthrax, in a subject.Type: GrantFiled: January 8, 2003Date of Patent: May 20, 2008Assignee: Biosite IncorporatedInventors: Gunars Edwin Valkirs, Kenneth Buechler
-
Patent number: 7368277Abstract: The invention relates to a technology by which antibodies directed to sources of infection in body fluids can be assayed with high accuracy, expediency and specificity. More particularly, the invention provides an antibody immunoassay method in which the antigen-antibody reaction between a target antibody in a sample and an assay antigen is conducted in the presence of an E. coli component and an antibody assay method which comprises using a reagent having a specific affinity for the Fc region of an antibody IgG as the antibody assay reagent.Type: GrantFiled: March 13, 2003Date of Patent: May 6, 2008Assignee: Otsuka Pharmaceutical Factory, Inc.Inventors: Tetsuya Tachikawa, Atsunari Noda, Kiyonori Katsuragi
-
Patent number: 7361480Abstract: The invention is directed to a method of detecting gluten-induced diseases such as e.g. celiac disease and dermatitis herpetiformis. Said diseases are indicated by the presence of autoantibodies against tissue transglutaminase tTG in the blood The test is carried out on a whole blood sample using tTG liberated from the red blood cells of the blood sample as an autoantigen. The liberated autoantigens react with the autoantibodies in the sample and form antigen-antibody complexes, which are detected. The presence of such complexes indicates the disease. The invention is also directed to the use of the autoantigen in a test and to a test-kit.Type: GrantFiled: April 24, 2002Date of Patent: April 22, 2008Inventors: Markku Mäki, Ilma Korponay-Szabo
-
Patent number: 7358052Abstract: Methods, compositions, kits, and a system are disclosed for detecting one or more analytes in a sample. A mixture comprising the (i) sample, (ii) a first binding reagent comprising a cleavage-inducing moiety and a first binding agent specific for an analyte, and (ii) one or more electrophoretic probes each having a second binding agent is subjected to conditions under which binding of respective binding agents occurs. The interaction between the binding agents and the analyte brings the cleavage-inducing moiety within a proximity effective for cleaving a cleavable linkage tethering an electrophoretic tag to the second binding agent, thereby releasing the tag for electrophoretic separation. Separation of different tags occurs by virtue of their distinct electrophoretic mobilities. After separation, a signal amplification moiety on each tag is activated to generate a signal to indicate the presence of a particular analyte in the sample.Type: GrantFiled: May 24, 2002Date of Patent: April 15, 2008Assignee: Monogram Biosciences, Inc.Inventor: Sharat Singh
-
Patent number: 7344846Abstract: The invention relates to methods for diagnosing and treating macular degeneration-related disorders. The invention also related to methods for identifying genes that cause macular degeneration-related disorders.Type: GrantFiled: August 16, 2005Date of Patent: March 18, 2008Assignee: University of Iowa Research FoundationInventors: Gregory S. Hageman, Robert F. Mullins
-
Patent number: 7344848Abstract: Monoclonal antibodies are provided which bind to heat-treated proteins of meats. The antibodies are useful in detecting the presence of an exogenous meat in a cooked or raw meat sample. Furthermore, the antibodies can be used to determine the end point temperature of a meat sample.Type: GrantFiled: December 19, 2003Date of Patent: March 18, 2008Assignee: Auburn UniversityInventor: Y.H. Peggy Hsieh
-
Patent number: 7344849Abstract: The present invention relates to assay methods for the determination of cobalamin or vitamin B12 in a body fluid and in particular to assay methods for the metabolically active pool of cobalamin, comprising contacting a cell free sample of a body fluid with an immobilised or immobilizable specific binding ligand for TC II or holo TC II, separating a ligand bound fraction from a non-ligand bound fraction and measuring the holo-TC II or TC-II bound cobalamin content therein.Type: GrantFiled: July 23, 2004Date of Patent: March 18, 2008Assignee: Axis-Shield ASAInventors: Erling Sundrehagen, Lars Örning
-
Patent number: 7335477Abstract: A recombinant, refolded non-fusion polypeptide expressed from a truncated r56 gene of the causative agent of scrub typhus, Orientia tsutsugamushi for the Karp, Kato and Gilliam strains has been produced. The invention is useful for detecting prior exposure to scrub typhus, screening for and/or identification of at least one infectious strain-similarity (i.e. a Karp-like, Kato-like or Gilliam-like strain) based on its strength of reaction toward a truncated protein and as a component in vaccine formulations and production of immune globulins for passive prophylaxis and immunity in subjects.Type: GrantFiled: April 12, 2002Date of Patent: February 26, 2008Assignee: The United States of America as represented by the Secretary of the NavyInventors: Wei-Mei Ching, Daryl J. Kelly, Gregory A. Dasch
-
Patent number: 7335724Abstract: The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue. The invention also relates to antibodies against the peptide and a method of detecting autoimmune antibodies.Type: GrantFiled: February 16, 2005Date of Patent: February 26, 2008Assignee: Stichting Voor de Technische WetenschappenInventors: Waltherus Jacobus Wilhelmus Van Venrooij, Gerardus Antonius Schellekens, Jozef Maria Hendrik Raats, Rene Michael Antonius Hoet
-
Patent number: 7297551Abstract: Recombinant fragments of Factor C are disclosed. These proteins and peptides show great potency in recognizing, binding to, neutralizing and removing endotoxin. These molecules can thus be used for anti-microbial, anti-endotoxin, and anti-sepsis therapy. SSCrFCES is a 38 kDa protein representing the LPS-binding domain of Factor C. The ability of SSCrFCES to bind lipid A was analyzed using an ELISA-based assay as well as surface plasmon resonance. Surface plasmon resonance similarly carried out for SSCrFC-sushi-1,2,3-GFP, SSCrFC-sushi-1GFP, and SSCrFC-sushi-3GFP confirmed their superior affinity for endotoxin. The 50% endotoxin-neutralizing concentration of SSCrFCES against 200 EU of endotoxin is 0.069 ?M, suggesting that SSCrFCES is an effective inhibitor of LAL coagulation cascade. Although partially attenuated by human serum, as low as 1 ?M of SSCrFCES inhibits the LPS-induced secretion of hTNF-? and hIL-8 by THP-1 and human pheripheral blood mononuclear cells with a potency more superior than polymyxin B.Type: GrantFiled: August 7, 2003Date of Patent: November 20, 2007Assignee: National University of SingaporeInventors: Jeak L. Ding, BoW Ho, Nguan S. Tan
-
Patent number: 7279295Abstract: The present invention relates to a novel allergen from timothy grass (Phleum pretense) pollen, Phl p11 as disclosed in SEQ ID NO:2, and use thereof as a reagent and in a diagnositic kit as well as for immunotherapy.Type: GrantFiled: March 27, 2003Date of Patent: October 9, 2007Assignee: Phadia ABInventors: Asa Marknell Dewitt, Verena Niederberger, Pirjo Lehtonen, Susanne Spitzauer, Wolfgang R. Sperr, Peter Valent, Rudolf Valenta, Jonas Lidholm
-
Patent number: 7270964Abstract: The invention is a method for detecting squalene in sera.Type: GrantFiled: July 9, 2004Date of Patent: September 18, 2007Assignee: United States of America as Represented by the Secretary of the ArmyInventors: Carl R Alving, Gary R Matyas, Nabila M Wassef, Mangala Rao
-
Patent number: 7264939Abstract: The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.Type: GrantFiled: November 10, 2005Date of Patent: September 4, 2007Assignee: Roche Diagnostics Operations, Inc.Inventors: Anneliese Borgya, Andreas Gallusser, Michael Grol, Klaus Hallermayer, Volker Klemt, Christoph Seidel
-
Patent number: 7264938Abstract: The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.Type: GrantFiled: November 10, 2005Date of Patent: September 4, 2007Assignee: Roche Diagnostics Operations, Inc.Inventors: Anneliese Borgya, Andreas Gallusser, Michael Grol, Klaus Hallermayer, Volker Klemt, Christoph Seidel
-
Patent number: 7258994Abstract: A method for diagnosing the likelihood and severity of cardiovascular disease in a patient is disclosed. The method determines the levels of antibodies against autoantigens, including myosin, oxidized LDL, ?-2-glycoprotein, heat shock protein-60, platelet glycoprotein, and immune complexes. It then compares the results to normal levels to determine the likelihood and severity of cardiovascular disease.Type: GrantFiled: January 9, 2006Date of Patent: August 21, 2007Assignee: Immunosciences Lab., Inc.Inventor: Aristo Vojdani
-
Patent number: 7255999Abstract: Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of post-translational modification activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in the post-translational modification of the target polypeptide.Type: GrantFiled: May 21, 2002Date of Patent: August 14, 2007Assignee: Monogram Biosciences, Inc.Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez
-
Patent number: 7252961Abstract: The invention relates to a method for the detection of an analyte in a competitive immunoassay in the presence of an analyte derivative and first and second receptor molecules, and to a kit for carrying out this detection method.Type: GrantFiled: July 17, 1997Date of Patent: August 7, 2007Assignee: Dade Behring Marburg GmbHInventors: Stephan Neuenhofer, Heinz-Jürgen Skrzipczyk, Peter Molz, Reinhard Käsmarker
-
Patent number: 7252951Abstract: The present invention relates to a new essential downstream component of the Wnt/Wingless (Wnt/Wg) signaling pathway and therapeutic and diagnostic applications based thereon. The invention relates to nucleotide sequences of the Drosophila melanogaster legless (lgs) gene, of its encoded proteins, as well as derivatives (e.g., fragments) and analogues thereof. The invention further includes vertebrate and invertebrate homologues of the Lgs protein, comprising proteins that contain a contiguous stretch of amino acids with similarity to the Drosophila lgs gene. The invention further relates to the function of the Drosophila and the human Lgs proteins. Methods for producing the Lgs proteins, derivatives and analogs, e.g., by recombinant means and antibodies to Lgs are provided by the present invention. In addition, the invention also relates to the therapeutic and diagnostic methods and compositions based on Lgs proteins and nucleic acids or fragments thereof.Type: GrantFiled: December 19, 2002Date of Patent: August 7, 2007Assignee: Universität ZurichInventors: Konrad Basler, Erich Brunner, Barbara Froesch, Thomas Kramps, Oliver Peter
-
Patent number: 7244580Abstract: The present invention relates to identification of polypeptides useful for generating antibodies specific for non-human IgE, particularly equine IgE. The invention, therefore, also relates to antibodies that specifically bind to IgE and methods to detect IgE using the antibodies. The invention also provides a kit for detection of IgE.Type: GrantFiled: November 8, 2001Date of Patent: July 17, 2007Assignee: The Regents of the University of CaliforniaInventors: Laurel J. Gershwin, Howard David Pettigrew, Warren V. Kalina
-
Patent number: 7238537Abstract: An analytical test device incorporating a dry porous carrier to which a liquid sample, eg. urine, suspected of containing an analyte such as HCG or LH can be applied indirectly, the device also incorporating a labelled specific binding reagent which is freely mobile in the porous carrier when in the moist state, and an unlabelled specific binding reagent which is permanently immobilized in a detection zone on the carrier material, the labelled and unlabelled specific binding reagents being capable of participating in either a sandwich reaction or a competition reaction in the presence of the analyte, in which prior to the application to the device of a liquid sample suspected of containing the analyte, the labelled specific binding reagent is retained in the dry state in a macroporous body, eg.Type: GrantFiled: September 4, 2001Date of Patent: July 3, 2007Assignee: Inverness Medical Switzerland GmbHInventors: Paul James Davis, Michael Evans Prior, Keith May
-
Patent number: 7235368Abstract: Use of calcineurin B homologous protein (CHP) from body fluids or body tissues as a marker peptide for diagnosis, for prognosis and for monitoring the course of inflammations and infections and/or as a target for therapeutically influencing the course of inflammations and/or infections.Type: GrantFiled: June 17, 2002Date of Patent: June 26, 2007Assignee: B.R.A.H.M.S AktiengesellschaftInventors: Andreas Bergmann, Joachim Struck, Monika Ühlein
-
Patent number: 7211409Abstract: A compound of formula (1) and an immunoassay method for quantitative determination of dioxins in a sample using as a standard the compound of the following formula (1): wherein R1, R2, R3 and R4 may be the same or different and represent chlorine or hydrogen, n is an integer from 1 to 10, and Z represents an amino acid residue or peptide.Type: GrantFiled: August 18, 2003Date of Patent: May 1, 2007Assignees: Toyo Boseki Kabushiki Kaisha, Takuma Co., Ltd.Inventors: Shigeaki Nishii, Kazuhiro Matsui, Takuya Ishibashi, Masanori Oka, Hiroki Fujihira, Hirotsugu Mishima, Shizuo Kataoka
-
Patent number: 7198904Abstract: A panel of monoclonal antibodies recognizing and binding to human inducible nitric oxide synthase (iNOS or type II iNOS) enzyme have been developed. The monoclonal antibodies may also be employed in an assay to detect the presence and/or quantitate the amount of human iNOS.Type: GrantFiled: April 7, 1997Date of Patent: April 3, 2007Inventor: Robert Webber
-
Patent number: 7195882Abstract: The present invention relates to monoclonal antibodies that specifically bind buprenorphine and/or at least one metabolic product thereof. The present invention further relates to buprenorphine metabolite conjugates for the production of monoclonal antibodies that specifically bind buprenorphine and/or at least one metabolic product thereof and hybridoma cells that produce the monoclonal antibodies. The invention also relates to immunoassay methods for determining buprenorphine and/or one or more buprenorphine metabolites in a sample using the novel antibodies and conjugates of the present invention.Type: GrantFiled: June 3, 2003Date of Patent: March 27, 2007Assignee: Roche Diagnostics Operations, Inc.Inventors: Richard T. Root, Mitali Ghoshal
-
Patent number: 7192786Abstract: This invention relates to a biospecific assay method, in which microparticles coated with the bioaffinity reactant A binding the analyte to be assayed; the sample to be analyzed, and the labelled bioaffinity reactant B are mixed. After the binding reaction the signal strength from the labelled bioaffinity reactant B bound to the microparticles is quantitated for the determination of the concentration of the analyte in the sample. According to the invention, such an amount of sample and microparticles is used in the assay that after binding of the analyte of the sample to the said amount of microparticles, each individual microparticle will emit such a signal strength as to allow the measurement of the analyte concentration over the whole range of typical analyte concentrations, and the signal strength from each microparticle is measured separately.Type: GrantFiled: June 7, 1995Date of Patent: March 20, 2007Assignee: Wallac OyInventors: Timo Nils-Erik Lövgren, Antti Juhana Iitiä, Kim Sverker Immanuel Pettersson
-
Patent number: 7192784Abstract: A substantial amount of a marker reagent associated with a measurement is measured in a marker reagent measurement area, and the substantial amount of the marker reagent is reflected by a result obtained in a reaction result measurement area where a reaction with a measurement target in an inspection target solution is measured. Thereby, an influence of external environmental factors, factors in a property of the inspection target solution, an erroneous operation in a measurement operation or the like is eliminated, whereby a chromatography measuring method employing a biosensor with higher accuracy and higher reliability can be provided.Type: GrantFiled: May 8, 2001Date of Patent: March 20, 2007Assignee: Matsushita Electric Industrial Co., Ltd.Inventors: Masataka Nadaoka, Mie Takahashi, Hirotaka Tanaka
-
Patent number: 7183065Abstract: The present invention relates to microbial UC pANCA antigens. The invention provides methods of diagnosing ulcerative colitis (UC) and methods of inducing tolerance in a pANCA-positive patient with UC using a histone H1-like antigen. The invention further provides methods of diagnosing UC and methods of inducing tolerance in a pANCA-positive patient with UC using a porin antigen. Methods of diagnosing UC and methods of inducing tolerance in a pANCA-positive patient with UC using a Bacteroides antigen also are provided.Type: GrantFiled: August 27, 2002Date of Patent: February 27, 2007Assignee: The Regents of the University of CaliforniaInventors: Jonathan Braun, Offer Cohavy
-
Patent number: 7169562Abstract: The invention relates to a process for detecting or determining a C-peptide-containing impurity in a sample of recombinantly produced human insulin or a derivative thereof, by a non-radioactive assay, comprising the steps: (a) preparing a sample of recombinantly produced human insulin or a derivative thereof; (b) mixing the samples with dilution buffer; (c) adding a tracer to mixture (b); (d) adding antibody specific for the C-peptide impurity to mixture (c); (e) adding “C-peptide second antibody bead” having at least one label to mixture (d); and (f) detecting or determining the presence of the C-peptide-containing impurity.Type: GrantFiled: October 26, 2000Date of Patent: January 30, 2007Assignee: Sanofi-Aventis Deutschland GmbHInventors: Martin Gerl, Cornelia Steinert
-
Patent number: 7166469Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.Type: GrantFiled: June 18, 2002Date of Patent: January 23, 2007Assignee: Leuven Research & Development VZWInventors: Paul N. Holvoet, Désiré J. Collen
-
Patent number: 7166440Abstract: An immunoassay of dioxins using 2,4,5-trichlorophenoxyalkyl amide derivative represented by the following formula (II) as an antigen for a competitive immunoassay is provided: where n is an integer of 1 to 10, and Z is a carrier compound or a label. This compound is not toxic, and is specific to dioxins and can be conjugated with a wide range of dioxin isomers, so that a safe and simple assay of dioxins can be provided.Type: GrantFiled: October 17, 2003Date of Patent: January 23, 2007Assignee: Takuma Co., Ltd.Inventors: Hiroki Fujihira, Kohei Nakatani
-
Patent number: 7157234Abstract: A microscale binding assay, analyte binding array, and kits are disclosed, which exploit the mass action law to harvest analyte from a liquid sample. This is achieved by fabrication of sorbent zones having up to ten times the binding capacity per unit area generally obtained on polystyrene microtiter plates. The resulting arrays substantially deplete the liquid solution of analyte during incubation. Accordingly, the assays respond to total mass of analyte in the sample, not analyte concentration. This approach, coupled with direct fluorescence detection in the NIR, yields maximal signal intensity and low background for optimal sensitivity.Type: GrantFiled: April 21, 1998Date of Patent: January 2, 2007Assignee: Beckman Coulter, Inc.Inventors: Robert J. Obremski, John W. Silzel, Tsong-Tseh Tsay, Bibijana Cercek, Charles L. Dodson, Tung Rung Wang, Yagang Liu, Zhou Shaomin
-
Patent number: 7148332Abstract: High affinity monoclonal antibodies for recognizing estrogen receptor (clone SP1) with immunohistochemistry and methods for creating such an antibody are disclosed. The lagomorph derived ER antibody provides a significant advantage over the currently available mouse ER antibodies in that there is no need for target retrieval when performing immunohistochemistry. Furthermore, the very low background when the lagomorph derived ER antibody is used in immunohistochemistry is also impressive. The immunohistochemistry comparative study with about fifty clinical specimens showed that the new ER (clone SP1) antibody had favorable results when compared to mouse monoclonal ER antibodies (clone 1D5). The lagomorph derived ER antibody may prove of great value in the assessment of ER status in human breast cancer. Humanized versions of the ER antibody may also provide therapeutic benefits.Type: GrantFiled: September 11, 2002Date of Patent: December 12, 2006Assignee: Spring BioscienceInventors: Haiying Xia, Zhida Huang
-
Patent number: 7144569Abstract: A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: (a) contacting a sample from the host with an agent selected from (i) the epitope comprising sequence which is: SEQ ID NO: 1 or 2, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO: 3, (ii) an epitope comprising sequence comprising: SEQ ID NO: 1, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO: 3, which epitope is an isolated oligopeptide derived from a gliadin protein, (ii) an analogue of (i) or (ii) which is capable of being recognised by a T cell receptor that recognises (i) or (ii), which in the case of a peptide analogue is not more than 50 amino acids in length, or (iv) a product comprising two or more agents as defined in (i), (ii) or (iii), and (b) determining in vitro whether T cells in the sample recognises the agent; recognition by the T cells indicating that the individual has, or is suType: GrantFiled: October 2, 2000Date of Patent: December 5, 2006Assignee: ISIS Innovation LimitedInventors: Robert Paul Anderson, Adrian Vivian Sinton Hill, Derek Parry Jewell
-
Patent number: 7141436Abstract: A sandwich immunoassay is disclosed that provides simple to perform yet sensitive identification of analytes in samples. All assay constituents needed (except analyte to be detected) for one assay are dried. Upon reconstitution with sample, a 10 to 15 minute incubation gives a rapid and convenient detection assay capability. The method incorporates the capture of antigen to an immobilized capture antibody. A labeled reporter antibody with the molecule, binds to the antigen to form an immunocomplex capable of generating a detectable signal.Type: GrantFiled: May 20, 2002Date of Patent: November 28, 2006Assignee: Science and Technology Corp.Inventors: Deborah L. Gatto-Menking, Michael T. Goode
-
Patent number: RE39664Abstract: The present invention relates to improved specific binding assay devices comprising a chromatographic medium including a reaction site at which a specific binding reagent is immobilized, a sample application well located adjacent to the chromatographic medium and offset upstream from the reaction site, and liquid absorption blotter offset downstream from the reaction site.Type: GrantFiled: November 21, 1995Date of Patent: May 29, 2007Assignee: Inverness Medical Switzerland GmbHInventors: Julian Gordon, Charles Stuart Gredell Pugh
-
Patent number: RE40535Abstract: An anti-KC-4 humanized monoclonal antibody that comprises the variable regions of the light and heavy chains of the anti-KC-4 murine antibody, wherein the light chain has 7 amino acids and the heavy chain has 12 amino acids of the framework regions substituted with amino acid present in equivalent positions in antibodies of a species other than munne, and the constant regions of a human antibody. The antibody may be labeled and/or glycosylated, and is presented as a composition with a carrier. The anti-KC-4 monoclonal antibody is used in diagnostic kits for cancer and in in vivo methods of imaging and treating a primary or metastasized cancer, and in vitro diagnosis and ex vivo purging neoplastic cells from a biological fluid. RNAs and DNAs encode the monoclonal antibody, and a hybrid vector carrying the nucleotides and transfected cells express the peptides.Type: GrantFiled: May 14, 2002Date of Patent: October 7, 2008Assignee: IBC Pharmaceuticals, Inc.Inventors: Fernando J. R. do Couto, Roberto L. Ceriani, Jerry A. Peterson
-
Patent number: RE40596Abstract: Monoclonal antibodies to rapamycin and to 40-O-alkylated derivatives of rapamycin are provided, together with novel haptens, immunogenic conjugates, and processes for making them and assay kits for using them.Type: GrantFiled: February 6, 2007Date of Patent: December 2, 2008Assignee: Novartis AGInventors: Richard Sedrani, Valerie Quesniaux Ryffel